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Introduction 
 Research in the field of Extracorporeal Pho-
topheresis (ECP) commenced in 1982.  Richard Edelson, 
MD, a Professor at Columbia University, had been experi-
menting with a therapy he invented as an alternative treat-
ment for untreatable cancers.  After many years of re-
search, he achieved an astonishing clinical success in the 
treatment of two patients with extensive cutaneous T-cell 
lymphoma (CTCL).  Previously, in the 1970’s, Dr. Edelson 
noted that removing circulating cancer cells from patients 
with Sezary Syndrome (SS), a form of CTCL, by way of re-
petitive Leukapheresis, resulted in a temporary improve-
ment in their skin disease.  Leukapheresis is a procedure 
that removes abnormal white blood cells from the 
blood.  It is a form of apheresis, which is the process of 
removing one particular constant from the blood and re-
turning the rest to circulation.  In the 1980’s, Dr. Edelson 
collaborated with Therakos, a Johnson and Johnson com-
pany, to design a device to accomplish Leukapheresis while 
simultaneously exposing a small amount of the patients’ 
white blood cells to Methoxsalen, a light sensitizing drug, 
and ultra violet (UVa) light to activate the medication. 
Immunity: Background Information 
 The immune system consists of differentiated 
hematopoietic cells that are created from bone marrow 
hematopoietic stem cells (HSC).  HSCs separate into vari-
ous types of blood components such as erythroid cells, 
platelets, myeloid cells (such as neutrophils, basophils, eo-
sinophils, monocytes), mast cells, natural killer cells, den-
dritic cells, natural killer T cells, thymus derived cells (T 
cells), and B cells depending on the environment and stim-
uli (Lensch, 2012).  These immune cells arrange host pro-
tection by responding to foreign antigens after the cells 
mature.  However, a proper maintenance of cellular and 
molecular balance is crucial for these immune responses 
to proceed.  Once this delicate balance is askew, normal 
immunity is disrupted and diseases with increased suscep-
tibility to infection arises. 
 Within the immune system, the Dendritic cells 
(DC) are antigen-presenting cells.  The DCs, also known as 
accessory cells, play an integral role in both inborn immun-
ity and adaptive immunity.  The cells link inborn and adap-
tive immunity by activating B and T-cells through the 
presentation of antigens on their cell surfaces (Novak, et 
al, 2010).  When B-cells are triggered by DCs, an immune 
response consisting of secretion of antigen specific anti-
bodies occurs.  Simultaneously, DCs activate CD4+ helper 
and CD8+ T-cells that define and stimulate T-cell responses 
specific to each antigen (Banchereau, Steinman, 
1998).  Depending on the nature of the antigen, different 
CD4+ T-helper (Th) responses such as Th-1, Th-2, Th-17, 
and T-regulation can occur.  Th-cells also secrete cytokines 
that promote cell interactions with additional cells, which 
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are then dispatched to the infected site.  For example, the 
Th-1 response is mediated by CD4+ helper T-cells and 
CD8+ T-5 cells that secrete IFN-γ, IL-2, and IL-12 to fight 
against viruses.  The CD4+ helper cells then “help” to in-
voke a cytotoxic attack against the virus, mainly through 
CD8+ cytotoxic T-cells (Steinman, Hemmi, 2006) 
(Kadowaki, 2007) . 
 Located in the immune system, T-regulatory cells 
(T-regs) regulate a wide variety of immune cells such as 
CD4+, CD8+, B-cells, natural killer T-cells, and antigen pre-
senting cells (APC)  both in vitro (artificial environment) 
and in vivo (natural environment).  These cells make up 5-
10% of the total agranulocytic cells found in the body’s 
blood (Sakaguchi, 2008).  They have the distinct ability to 
regulate reactions in the immune system, preventing im-
mune diseases such as allergies and autoimmunity.  T-regs 
have often been recognized as the cause for failure of can-
cer vaccines.  On the other hand, T-regs also have potential 
use for patients with irregular immune systems.  In autoim-
mune patients, an increase in T-regs may be an ideal meth-
od of treatment since their immune system is compro-
mised and these cells could help regulate it.  Similarly, the 
removal of T-regulatory cells may assist in increasing a cy-
totoxic response to tumor antigens. 
Cutaneous T-cell Lymphoma (CTCL) 
 Cutaneous T-cell lymphoma (CTCL) is a heteroge-
neous group of non-Hodgkin’s peripheral T-cell lymphomas 
that mainly affect the skin.  Two of the most common 
forms of CTCL are Mycosis Fungoides (MF) and Sézary Syd-
rome (SS).  They are distinguished by malfunctioning CD4+ 
T-cells and impaired immunity.  Together they encompass 
approximately 70% of all CTCL cases.  About 1,500 new 
cases of MF/SS are reported yearly, and there are currently 
16,000-20,000 individuals living in the United States with 
MF/SS (Criscione, Weinstock, 2007).  CTCLs are incurable 
and thought to arise from uncontrolled reproduction and 
accumulation of atypical mature helper, memory clonal T-
lymphocytes (Vonderheid, Bernengo, 2003).   
Sézary Syndrome (SS) 
 Discovered and introduced by Albert Sézary in 
1938, Sézary Syndrome (SS) is a form of leukemia con-
sisting of cells with cerebriform shaped nuclei, itching, ex-
foliative dermatitis, and adenopathy (inflammation of the 
lymph nodes).  Patients with SS do not have a good prog-
nosis; there is an average survival rate of only 3 years 
(Scarisbrick, et al, 2001).  SS patients have been found to 
have a high rate of Staph colonization. Secondary and hos-
pital acquired infections, most often from Staphylococcus 
aureus (Staph) sepsis due to an impaired immune system, 
breaks in the skin and use of catheters are particularly fatal 
in SS patients.    The cause of SS is unknown and the diag-
nosis is very difficult due to its similarities to other skin ail-
ments.  It was originally believed that SS was derived from 
MF.  However, MF and SS can be differentiated since MF 
cells are effector memory T-cells and SS cells are central 
memory T-cells.  With Sèzary cells, they are also found in 
both the blood and skin with CD4+ T cells lacking the ex-
pression of CD-26 or CD-7. (Campbell, et al, 2010) 
Graft-versus-Host Disease (GvHD) 
 Graft-versus-host disease (GvHD) is an immune 
system disorder that limits the use of stem cell and bone 
marrow transplant therapies.  The donor immune cells 
used in the transplant recognize host cells as being foreign, 
based on human leukocyte antigen (HLA) mismatch.  The 
donor cells mount an immunological attack, resulting in 
damage to organs including the skin, gut, liver, eyes, or 
lungs. 
 There are two types of GVHD, acute GVHD and 
chronic GVHD.  Symptoms occurring within 100 days post-
transplant are described as acute GVHD and any occur-
rence of symptoms beyond 100 days are characterized as 
chronic GVHD.  An analysis of acute GVHD showed that 
amongst the patients affected 81% had skin involvement, 
54% had gastrointestinal involvement, and 50% had liver 
involvement (Martin, et al, 1990).  Candidates for trans-
plant therapies have a plethora of ailments which can lead 
to  incrased numbers of antigen presenting cells resulting 
from damages produced  by a multitude of factors such as 
underlying disease and its treatmentvia chemotherapy, 
radiation, and infections.  In order to prepare the host’s 
body for transplantation, the patient has to undergo a pro-
cedure called total body irradiation. Total body irradiation 
is used to suppress the immune system, thus preventing 
the patient’s immune system from destroying implanted 
cells that are foreign to the body.  During this procedure, 
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inflammatory cytokines such as IL-1 and tumor necrosis 
factors (TNF) are secreted from the patient’s tis-
sues.  Cytokines, which can potentially cause damage to 
the gastrointestinal tract via endothelial apoptosis, may 
increase the severity of GvHD if the microbial products 
such as bacteria attack the blood system.  Activation of the 
immune system or tolerance by the body is controlled by 
APC’s that are activated by these secretions (Roncarolo, et 
al, 2001). 
 In the cells there is a major histocompatibililty 
complex (MHC).  The MHC is a set of molecules on the sur-
face of the cells which facilitates the interactions of leuko-
cytes (WBCs).  CD4+ and CD8+ T-cells, and cytokines are 
the main disease facilitators.  In every individual, the MHC 
takes on its own unique genetic coding.  One of the prima-
ry functions of the MHC is the recognition of foreign anti-
gens invading the immune system. Since the MHC is highly 
polymorphic, it has the ability to recognize countless types 
of antigens.  It then binds peptide fragments taken from 
the pathogens and displays them on the cell surface for 
recognition by the T-cells.  The MHC presents the antigens 
to the T-cell receptor (TCR), and the T-cells are activated or 
deactivated via an interaction between the TCR and the 
MHC.  In the case of GvHD, everything is awry because the 
grafted T-cells fail to recognize the MHC proteins on host 
cells.  Due to the MHC mismatch, the graft T-cells attack 
the host cells thinking they are foreign even though they 
are non-antigenic. Thus, the MHC mismatch contributes to 
the disrupted normal immunity leading to GVHD. 
Extracorporeal Photopheresis (ECP) 
 Extracorporeal Photopheresis is a pioneering treat-
ment with minimal side effects, which improves the quality 
of life, and has increased the survival rates for persons 
with select incurable diseases.  Based on clinical trials, the 
procedure was approved by the FDA for treatment of 
erythrodermic Leukemic-CTCL (L-CTCL) (Edelson, et al, 
1987). At the time, response rates between 54% and 66% 
had been reported in L-CTCL patients with about 10% com-
plete responders (Jiang, et al, 1999) (Crovetti, et al, 
2000).  This opened up a new world of possibilities in the 
treatment of cancers. Most cancer treatments come with a 
large amount of side effects along with the possibility of a 
cure.  This treatment had the potential of accomplishing 
the latter, with almost no risk of side effects.   
 In the ECP procedure that was created by the 
Therakos company, blood is drawn from the arm or a cen-
tral catheter, and a very small amount (5x109) of the pa-
tients white blood cells (3-5%) are separated and collected 
for irradiation or apheresis.  The blood is centrifuged to 
separate the leukocyte enriched blood portion from the 
red blood cells in plasma. The rest of the blood is automati-
cally returned to the bloodstream. The collected white 
blood cells are then treated with a medicine called Meth-
oxsalen/Uvadex.  The drug is activated when it is exposed 
to ultra-violet (UV) light. The medicated white blood cells 
are exposed to UVa light, with a strength of 1.5 J/
cm^2.  The function of the medication is to covalently bind 
and cross-link DNA, leading to apoptosis of treated 
cells.  These cells are now known as Methoxsalen treated 
buffy coat cells.  The buffy coat cells are then re-infused 
back into the patient . so that they can cause an immune 
response.  In the body, the spleen and the liver now pick 
up the Methoxsalen treated white blood cells. The day 
after ECP treatment, the treated cells undergo apoptosis. 
Even though the mechanism is not understood, these cells 
are phagocytized by antigen presenting cells (APC) that are 
causing disorder in the body.  It is theorized that the phag-
ocytosis causes a regulation of immune responses by alter-
ing the APC function.  The APC’s now become immunologi-
cal tolerant inducing or tolerogenic to the immune sys-
tem.  The phagocytosis causes a decrease in the secretion 
of pro-inflammatory cytokines and effector T-
cells.  Additionally, it causes an increase in anti-
inflammatory cytokines such as TGF-beta and IL-10.  This 
process and reaction causes a boost in the activation and 
stimulation of T-regulatory cells which in turn leads to a 
healthy regeneration and rebalancing of the T-cells and 
other immune cells in the body.  Additionally, blood that 
has been irradiated halts lymphocytes from causing harm 
to patients who have compromised immune systems.  ECP 
does not cause any known harm to the body, and the 
blood does not become radioactive or toxic. 
 Since there was some understanding as to how 
ECP was able to achieve these positive results, it brought 
about the possibility of expanding its usage for other se-
vere diseases.  These diseases include: multiple sclerosis 
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(MS), systemic sclerosis, Crohn’s disease, rheumatoid ar-
thritis, type-1-diabetes, and autoimmune diseases such as 
lupus.  Trials have also begun in cases of whole transplant-
ed organ rejection. In CTCL patients, ECP has shown the 
successful destruction of malignant T-cells via apoptosis 
and the differentiation of monocytes into effective antigen 
presenting dendritic cells. These two outcomes concur-
rently lead to a decrease of the tumor load and initiation 
of antitumoral immune response. (Garban, et al, 2012). 
Studies 
 Studies have shown the efficacy of ECP treatment 
in patients with early-stage mycosis fungoides (MF).  The 
studies were conducted with ECP as a mono-therapy and 
as a supplement to the traditional cancer therapies.  The 
patients underwent treatment of ECP for two days every 
four weeks over a time span of six months.  Those that had 
a partial response continued the treatment of ECP for the 
full six months and those without an initial response added 
oral bexarotene and/or interferon α.  These studies pro-
duced astonishingly positive results.   
 Participants included nineteen patients with early-
stage MF (7 men, 12 women; 16 white, 3 African Ameri-
can) with an average age of 63.5 years (range, 46-85 
years). 42% of the participants responded to the ECP by 
itself with an average amount of 12 ECP sessions over 12 
months (8/19; including 7 partial response, 1 complete 
response).  Seven of the patients with stabilized MF at 3 
months received additional bexarotene treatment (3/5; 1 
complete response) or were  administered bexarotene 
plus interferon α (1/2), and 57% (4/7) responded to the 
updated treatment. Side effects were limited to those ex-
pected with standard chemotherapy treatment. The 
effects included nausea, vomiting, and diarrhea. 
 The studies proved that ECP is effective for pa-
tients with early-stage MF alone or in combination with 
drugs and included improved quality of life. It has shown a 
response of as high as 42% with ECP treatment alone 
(Talpur, et al, 2011) 
 Another study was on the efficacy of ECP on ster-
oid-dependent acute GVHD.  A complete resolution was 
attained in 82% of patients with skin involvement, 61% 
with liver involvement, and 61% with gut involve-
ment.  These patients received ECP on 2 consecutive days 
every one to two weeks, until there was a noticeable re-
sponse and continued every two to four weeks until it 
reached a maximum response. The next stage conducted 
was a study of the relationship of mortality and survival. 
The 4-year survival rate for those in whom acute GVHD 
had a complete response was 59% (Kumar, 2011).    
 When ECP was first introduced into the medical 
world, it was only proven to work on CTCL and GvHD.  Due 
to the success, the research community continued looking 
to see which other ailments the treatment could be ap-
plied to.  This has become a worldwide concerted effort in 
attempt to make headway in previously incurable diseases 
and clinical trials have begun on the effect of ECP on many 
different unrelated or atypical diseases..   
 Another case where the curative effects of ECP 
can be observed is through studies involving patients 
afflicted with Crohn’s disease, who are incapable of re-
sponding to alternative treatments such as immune-
suppressants and/or anti-TNF therapies.  After twelve se-
quential weeks of treatment, the success of the individu-
al’s results were evaluated based on the patient’s decrease 
in their Crohn's Disease Activity Index (CDAI) of less than 
or equal to 100 points, or the remission which can be char-
acterized by an index of less than 150 points. From the 28 
patients that participated in the study, half successfully 
responded to the treatment with 13 subjects reacting at 
week 6, and 7 of them obtaining remission after the 12-
week interval.  From the 12 patients who chose to advance 
with a 12-week extension study, 9 continued to effectively 
respond to the treatment. Through their study, clinicians 
were capable in discerning ECP as a productive means in 
which patients with Crohn’s disease were able to attain 
desirable results (Abreu et. al.. 2009). 
Conclusion 
 Beginning with the initial successes in the 1980’s, 
extracorporeal photophersis has been a medical break-
through in a field where there rarely is a cure found 
with  limited or no side effects.  The difficulty of under-
standing how it achieves its results has not been a deter-
rent to further expansion of its usage.  Today, ECP is at the 
forefront of clinical trials bringing hope to many with lim-
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to ultra-violet (UV) light. The medicated white blood cells 
are exposed to UVa light, with a strength of 1.5 J/
cm^2.  The function of the medication is to covalently bind 
and cross-link DNA, leading to apoptosis of treated 
cells.  These cells are now known as Methoxsalen treated 
buffy coat cells.  The buffy coat cells are then re-infused 
back into the patient . so that they can cause an immune 
response.  In the body, the spleen and the liver now pick 
up the Methoxsalen treated white blood cells. The day 
after ECP treatment, the treated cells undergo apoptosis. 
Even though the mechanism is not understood, these cells 
are phagocytized by antigen presenting cells (APC) that are 
causing disorder in the body.  It is theorized that the phag-
ocytosis causes a regulation of immune responses by alter-
ing the APC function.  The APC’s now become immunologi-
cal tolerant inducing or tolerogenic to the immune sys-
tem.  The phagocytosis causes a decrease in the secretion 
of pro-inflammatory cytokines and effector T-
cells.  Additionally, it causes an increase in anti-
inflammatory cytokines such as TGF-beta and IL-10.  This 
process and reaction causes a boost in the activation and 
stimulation of T-regulatory cells which in turn leads to a 
healthy regeneration and rebalancing of the T-cells and 
other immune cells in the body.  Additionally, blood that 
has been irradiated halts lymphocytes from causing harm 
to patients who have compromised immune systems.  ECP 
does not cause any known harm to the body, and the 
blood does not become radioactive or toxic. 
 Since there was some understanding as to how 
ECP was able to achieve these positive results, it brought 
about the possibility of expanding its usage for other se-
vere diseases.  These diseases include: multiple sclerosis 
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(MS), systemic sclerosis, Crohn’s disease, rheumatoid ar-
thritis, type-1-diabetes, and autoimmune diseases such as 
lupus.  Trials have also begun in cases of whole transplant-
ed organ rejection. In CTCL patients, ECP has shown the 
successful destruction of malignant T-cells via apoptosis 
and the differentiation of monocytes into effective antigen 
presenting dendritic cells. These two outcomes concur-
rently lead to a decrease of the tumor load and initiation 
of antitumoral immune response. (Garban, et al, 2012). 
Studies 
 Studies have shown the efficacy of ECP treatment 
in patients with early-stage mycosis fungoides (MF).  The 
studies were conducted with ECP as a mono-therapy and 
as a supplement to the traditional cancer therapies.  The 
patients underwent treatment of ECP for two days every 
four weeks over a time span of six months.  Those that had 
a partial response continued the treatment of ECP for the 
full six months and those without an initial response added 
oral bexarotene and/or interferon α.  These studies pro-
duced astonishingly positive results.   
 Participants included nineteen patients with early-
stage MF (7 men, 12 women; 16 white, 3 African Ameri-
can) with an average age of 63.5 years (range, 46-85 
years). 42% of the participants responded to the ECP by 
itself with an average amount of 12 ECP sessions over 12 
months (8/19; including 7 partial response, 1 complete 
response).  Seven of the patients with stabilized MF at 3 
months received additional bexarotene treatment (3/5; 1 
complete response) or were  administered bexarotene 
plus interferon α (1/2), and 57% (4/7) responded to the 
updated treatment. Side effects were limited to those ex-
pected with standard chemotherapy treatment. The 
effects included nausea, vomiting, and diarrhea. 
 The studies proved that ECP is effective for pa-
tients with early-stage MF alone or in combination with 
drugs and included improved quality of life. It has shown a 
response of as high as 42% with ECP treatment alone 
(Talpur, et al, 2011) 
 Another study was on the efficacy of ECP on ster-
oid-dependent acute GVHD.  A complete resolution was 
attained in 82% of patients with skin involvement, 61% 
with liver involvement, and 61% with gut involve-
ment.  These patients received ECP on 2 consecutive days 
every one to two weeks, until there was a noticeable re-
sponse and continued every two to four weeks until it 
reached a maximum response. The next stage conducted 
was a study of the relationship of mortality and survival. 
The 4-year survival rate for those in whom acute GVHD 
had a complete response was 59% (Kumar, 2011).    
 When ECP was first introduced into the medical 
world, it was only proven to work on CTCL and GvHD.  Due 
to the success, the research community continued looking 
to see which other ailments the treatment could be ap-
plied to.  This has become a worldwide concerted effort in 
attempt to make headway in previously incurable diseases 
and clinical trials have begun on the effect of ECP on many 
different unrelated or atypical diseases..   
 Another case where the curative effects of ECP 
can be observed is through studies involving patients 
afflicted with Crohn’s disease, who are incapable of re-
sponding to alternative treatments such as immune-
suppressants and/or anti-TNF therapies.  After twelve se-
quential weeks of treatment, the success of the individu-
al’s results were evaluated based on the patient’s decrease 
in their Crohn's Disease Activity Index (CDAI) of less than 
or equal to 100 points, or the remission which can be char-
acterized by an index of less than 150 points. From the 28 
patients that participated in the study, half successfully 
responded to the treatment with 13 subjects reacting at 
week 6, and 7 of them obtaining remission after the 12-
week interval.  From the 12 patients who chose to advance 
with a 12-week extension study, 9 continued to effectively 
respond to the treatment. Through their study, clinicians 
were capable in discerning ECP as a productive means in 
which patients with Crohn’s disease were able to attain 
desirable results (Abreu et. al.. 2009). 
Conclusion 
 Beginning with the initial successes in the 1980’s, 
extracorporeal photophersis has been a medical break-
through in a field where there rarely is a cure found 
with  limited or no side effects.  The difficulty of under-
standing how it achieves its results has not been a deter-
rent to further expansion of its usage.  Today, ECP is at the 
forefront of clinical trials bringing hope to many with lim-
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ited options or where the cure is sometimes just as deadly 
as the disease, as is the case in chemotherapy and radia-
tion treatments.  With its versatility, ECP becomes an addi-
tional option even for patients already using other thera-
pies.  Trials have produced extremely promising results for 
diseases with little or no hope.  To date, ECP has only been 
approved for treatment in CTCL and GvHD, but current 
trials are expanding its usage.  ECP has promising potential 
to be the cure of the future pertaining to immune system 
related diseases. 
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Introduction 
The Epidermal Growth Factor Receptor (EGFR), also known 
as ErbB1 or Her1 in humans, was first discovered by Stan-
ley Cohen in the 1970’s (Yarden, Sliwkowski, 2001).  Since 
then, our understanding of the protein and its critical role 
in numerous forms of cancer has advanced in enormous 
strides.  Advances in this area have proven to be fruitful, 
and much hope is put into future development for cancer 
cures.  EGFR is now understood to be one of four members 
of the ErbB interactive family of Tyrosine Kinase (TK) Pro-
teins.  EGFR, as well as ErbB 2, 3, and 4 (Her 2, 3, 4) are 
phosphorylation inducing proteins on the Tyrosine portion 
of the receptors (Yarden, Sliwkowski, 2001).  EGFR carries 
out numerous signal transduction pathways which result in 
cellular proliferation, metastasis, and apoptotic aversion, 
all clearly oncogenic activities.  Consequently, EGFR com-
monly causes numerous types of cancers whenever-
expressed in epithelial tissue throughout the body (Heist, 
Christiani, 2009).  In Non Small Cell Lung Cancer (NSCLC) 
specifically, EGFR over expression is the most common 
cause, leading to much research and analysis of this pro-
tein, and its mutations in regard to lung cancer.  Numerous 
drug therapies have been developed to target the specific 
mutations that were found as causes of 
NSCLC.  Understanding of the structure and mechanism of 
this protein is crucial to the development of biomarkers to 
target specific populations containing the mutation to al-
low for further development of target therapy for cancer.   
Methods 
Various databases were utilized to gather papers on re-
search studies and reviews on the subject matter to ana-
lyze it and determine possible biomarker methods and 
their efficiency.  Articles were found in Google Scholar, 
Touro Library Database, and Rutgers University Data-
base.  These papers were analyzed and used to come to 
the conclusions explained in the discussion of this paper. 
Results: 
EGFR 
EGFR is a tri-domain membranous receptor protein con-
sisting of an extracellular ligand-binding domain mainly 
comprised of cysteine, a hydrophobic transmembranous 
area, and an intracellular Tyrosine Kinase Domain (Yarden, 
2001).  The Tyrosine Kinase domain is made up of a jux-
tamembrane region, an area for TK activity, and a C -
terminal domain (Markus, Alain, 2013).  A number of lig-
ands contain an affinity to EGFR including the Transforming 
Growth Factor-α (TGF-α), Epidermal Growth Factor (EGF) 
and Amphiregulin (Figure 1) (Huang, Harari,1999).  All 
EGFR ligands contain around 50 amino acids including six 
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